Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Relapsed or refractory multiple myeloma Draft recommendations posted for stakeholder feedback: March 7, 2024 End of feedback period: March 22, 2024 Draft Recommendation